Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo

Biomedicine and Pharmacotherapy

Volumn 67, Issue 4, 2013, Pages 337-345

  Jin, Yanling ^a   Mao, Jun ^a   Wang, Huanxi ^a   Hou, Zhenhuan ^a   Ma, Wei ^a   Zhang, Jun ^a   Wang, Bo ^a   Huang, Yuhong ^a   Zang, Shizhu ^a   Tang, Jianwu ^a   Li, Lianhong ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

JNK signal transduction pathway; Liver cancer stem cells; Lymph node metastasis (LNM)

Indexed keywords

CD133 ANTIGEN; SYNEXIN; UVOMORULIN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; ASCITES; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ACTIVATING TRANSCRIPTION FACTOR 2; ANIMALS; ANNEXIN A7; ANTIGENS, CD; ASCITES; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PEPTIDES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84876887518     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.02.006     Document Type: Article

References (45)

1. Fernández M., Semela D., Bruix J., Colle I., Pinzani M., Bosch J. Angiogenesis in liver disease. J Hepatol 2009, 50:604-620.
2. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
4. Croker A.K., Allan A.L. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008, 12:374-390.
5. Chen H.C., Chou A.S., Liu Y.C., Hsieh C.H., Kang C.C., Pang S.T., et al. Induction of metastatic cancer stem cells from the NK/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN-γ. Lab Invest 2011, 91:1502-1513.
6. Hou L., Li Y., Jia Y.H., Wang B., Xin Y., Ling M.Y., et al. Molecular mechanism about lymphogenous metastasis of hepatocarcinoma cells in mice. World J Gastroenterol 2001, 7:532-536.
7. Song B., Tang J.W., Wang B., Cui X.N., Hou L., Sun L., et al. Identify lymphatic metastasis-associated genes in mouse hepatocarcinoma cell lines using gene chip. World J Gastroenterol 2005, 11:1463-1472.
8. Liu S., Sun M.Z., Tang J.W., Wang Z., Sun C., Greenaway F.T., et al. High-performance liquid chromatography/nano-electrospray ionization tandem mass spectrometry, two-dimensional difference in-gel electrophoresis and gene microarray identification of lymphatic metastasis-associated biomarkers. Rapid Commun Mass Spectrom 2008, 22:3172-3178.
9. Sun M.Z., Liu S., Tang J., Wang Z., Gong X., Sun C., et al. Proteomics analysis of two mice hepatocarcinoma ascites syngeneic cell lines with high and low lymph node metastasis rates provide potential protein markers for tumor malignancy attributes to lymphatic metastasis. Proteomics 2009, 9:3285-3302.
10. Zhang J., Song M., Wang J., Sun M., Wang B., Li R., et al. Enoyl coenzyme A hydratase 1 is an important factor in the lymphatic metastasis of tumors. Biomed Pharmacother 2011, 65:157-162.
11. Song M.Y., Tang J.W., Sun M.Z., Liu S.Q., Wang B. Localization and expression of CLIC1 in hepatocarcinoma ascites cell lines with high or low potentials of lymphatic spread. Zhonghua Bing Li Xue Za Zhi 2010, 39:463-466.
12. He L., Zhang J., Jiang L., Jin C., Zhao Y., Yang G., et al. Differential expression of Axl in hepatocellular carcinoma and correlation with tumor lymphatic metastasis. Mol Carcinog 2010, 49:882-891.
13. Cui X.N., Tang J.W., Hou L., Song B., Ban L.Y. Identification of differentially expressed genes in mouse hepatocarcinoma ascites cell line with low potential of lymphogenous metastasis. World J Gastroenterol 2006, 12:6893-6897.
14. Chu H., Zhou H., Liu Y., Liu X., Hu Y., Zhang J. Functional expression of CXC chemokine recepter-4 mediates the secretion of matrix metalloproteinases from mouse hepatocarcinoma cell lines with different lymphatic metastasis ability. Int J Biochem Cell Biol 2007, 39:197-205.
15. Zhou H., Jia L., Wang S., Wang H., Chu H., Hu Y., et al. Divergent expression and roles for caveolin-1 in mouse hepatocarcinoma cell lines with varying invasive ability. Biochem Biophys Res Commun 2006, 345:486-494.
16. Suetsugu A., Nagaki M., Aoki H., Motohashi T., Kunisada T., Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006, 351:820-824.
17. Yin S., Li J., Hu C., Chen X., Yao M., Yan M., et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007, 120:1444-1450.
18. Ma S. Biology and clinical implications of CD133(+) liver cancer stem cells. Exp Cell Res 2013, 319:126-132.
19. Zhang J., Luo N., Luo Y., Peng Z., Zhang T., Li S. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol 2012, 40:747-756.
20. Ma S., Tang K.H., Chan Y.P., Lee T.K., Kwan P.S., Castilho A., et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010, 7:694-707.
21. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
22. Zhang Y.H., Wang S.Q., Sun C.R., Wang M., Wang B., Tang J.W. Inhibition of JNK1 expression decreases migration and invasion of mouse hepatocellular carcinoma cell line in vitro. Med Oncol 2011, 28:966-972.
23. Qazi A.S., Sun M., Huang Y., Wei Y., Tang J. Subcellular proteomics: determination of specific location and expression levels of lymphatic metastasis associated proteins in hepatocellular carcinoma by subcellular fractionation. Biomed Pharmacother 2011, 65:407-416.
24. Jin YL, Wang ZQ, Qu H, Wang HX, et al. Annexin A7 gene is an important factor in the lymphatic metastasis of tumors. Biomed Pharmacother [in press].
25. van der Wurff A.A., Arends J.W., van der Linden E.P., ten Kate J., Bosman F.T. L-CAM expression in lymph node and liver metastases of colorectal carcinomas. J Pathol 1994, 172:177-181.
26. Yang Z., Zhang L., Ma A., Liu L., Li J., Gu J., et al. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One 2011, 6:e28405.
27. Curtin J.C., Lorenzi M.V. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010, 1:563-577.
28. Dubrovska A., Kim S., Salamone R.J., Walker J.R., Maira S.M., García-Echeverría C., et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 2009, 106:268-273.
29. Ou J., Pan F., Geng P., Wei X., Xie G., Deng J., et al. Silencing fibronectin extra domain A enhances radiosensitivity in nasopharyngeal carcinomas involving an FAK/Akt/JNK pathway. Int J Radiat Oncol Biol Phys 2012, 82:e685-e691.
30. Veit C., Genze F., Menke A., Hoeffert S., Gress T.M., Gierschik P., et al. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res 2004, 64:5291-5300.
31. Wakamatsu Y., Sakamoto N., Oo H.Z., Naito Y., Uraoka N., Anami K., et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int 2012, 62:112-119.
32. Neuzil J., Stantic M., Zobalova R., Chladova J., Wang X., Prochazka L., et al. Tumour-initiating cells vs. cancer " stem" cells and CD133: what's in the name?. Biochem Biophys Res Commun 2007, 355:855-859.
33. Wei X.D., Zhou L., Cheng L., Tian J., Jiang J.J., Maccallum J. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Head Neck 2009, 31:94-101.
34. You H., Ding W., Rountree C.B. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010, 51:1635-1644.
35. Ding W., Mouzaki M., You H., Laird J.C., Mato J., Lu S.C., et al. CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology 2009, 49:1277-1286.
36. Rountree C.B., Barsky L., Ge S., Zhu J., Senadheera S., Crooks G.M. A CD133-expressing murine liver oval cell population with bilineage potential. Stem Cells 2007, 25:2419-2429.
37. Rountree C.B., Ding W., He L., Stiles B. Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells 2009, 27:290-299.
38. Rountree C.B., Senadheera S., Mato J.M., Crooks G.M., Lu S.C. Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology 2008, 47:1288-1297.
39. Tang K.H., Ma S., Lee T.K., Chan Y.P., Kwan P.S., Tong C.M., et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012, 55:807-820.
40. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
41. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
42. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 13:313-323.
43. Ma S., Chan K.W., Hu L., Lee T.K., Wo J.Y., Ng I.O., et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132:2542-2556.
44. Piao L.S., Hur W., Kim T.K., Hong S.W., Kim S.W., Choi J.E., et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 2012, 315:129-137.
45. Chien M.H., Yeh K.T., Li Y.C., Hsieh Y.H., Lin C.H., Weng M.S., et al. Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma. J Surg Oncol 2011, 104:299-304.